Company intelligence / Profile preview

ST Biosciences

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

ST Biosciences is a South Korean biotechnology company focused on developing innovative therapies for liver diseases and oncology. The company leverages a proprietary platform targeting the Hepatitis B virus X (HBx) protein, which plays a critical role in the progression of chronic hepatitis B to hepatocellular carcinoma. Their pipeline includes small molecule inhibitors designed to disrupt viral replication and oncogenic signaling pathways. Additionally, ST Biosciences is exploring combination therapies involving immune checkpoint inhibitors to enhance treatment efficacy in solid tumors. The company aims to address significant unmet medical needs in the field of viral-associated cancers.

Therapeutic areas: Oncology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on ST Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ST Biosciences.

Explore the full profile